
Nov 16, 2026 · 56 min
Candel bets on in situ immunization for prostate cancer
Preparing For Commercial Launch In Oncology With Candel Therapeutics' Paul Peter Tak, M.D., Ph.D.
The episode examines whether Candel can translate promising immune biology into a credible, affordable launch for localized prostate cancer.
- 1Candel’s aglatimogene program aims to turn treated tumors into personalized vaccines while remaining an off-the-shelf therapy.
- 2Disease-free survival anchors the regulatory case, with FDA engagement shaping clinical, manufacturing, and analytical evidence for a potential BLA.
- 3Candel plans to limit fixed costs by outsourcing much of its launch infrastructure and targeting concentrated specialist accounts.
Don't miss
Tak explains how Candel aims to turn an injected tumor into the source of a systemic immune response while keeping the treatment off the shelf.
The brief
Paul Peter Tak, CEO of Candel Therapeutics, describes the company’s path toward a potential BLA for aglatimogene in localized prostate cancer.
Candel’s adenovirus-based therapy delivers a gene into the tumor, then uses a prodrug to trigger immunogenic cell death and release antigens that can activate systemic immunity.
The regulatory case turns on disease-free survival in curative-intent prostate cancer, while FDA engagement has helped shape manufacturing, comparability, biodistribution, and immune-activation evidence.
Rather than build every capability internally, Candel plans to outsource manufacturing, clinical operations, and much of commercialization before bringing a focused sales force in-house after approval.
Tak’s broader launch lesson is to delay fixed costs until uncertainty falls, allocate capital according to risk, and keep scientific rigor and patient benefit central.
What was said on this episode
18 statements · 15 positive · 3 negative
- Paul Peter Takon Rigorous medical researchPositive2:29
Rigorous research can improve patients’ lives and advance remission or cure.
“I've tried to improve the life of patients through very rigorous research focused on the next big thing for patients to really get patients into remission of their disease activity and start to think about cure.”
Listen at 2:29
- Paul Peter Takon Immune checkpoint inhibitorsNegative5:41
Many patients do not respond or later lose response to checkpoint inhibitors.
“many patients will not respond to immune checkpoint inhibitors or may lose response”
Listen at 5:41
- Paul Peter Takon Candel adenovirus therapyPositive11:59
Candel’s therapy uses a replication-defective adenovirus to deliver HSV thymidine kinase.
“we use a replication defective adenovirus that's injected into a tumor to deliver a certain gene, which is called the HSV thimerine kinase gene”
Listen at 11:59
- Paul Peter Takon Candel prodrug treatmentPositive12:39
The activated prodrug induces extensive tumor-cell death.
“the prodrug will be activated and will be turned into a toxic metabolite, so-called nucleotide analog, that will induce massive cell death in the tumor”
Listen at 12:39
- Paul Peter Takon Candel viral immunotherapyPositive13:36
The therapy generates systemic immunity against injected and distant tumors.
“this leads to a systemic anti-tumor immune response against the injected tumor, but also against the uninjected distant metastasis”
Listen at 13:36
- Paul Peter Takon Candel viral immunotherapyPositive13:47
The treatment may require only two or three administrations over a patient’s lifetime.
“You only need to do it twice or three times in a patient's life to teach the patient's own immune system how to start to control the tumor.”
Listen at 13:47
- Paul Peter Takon Candel viral immunotherapyPositive14:00
Clinical trials suggest the therapy improves patient outcomes.
“We've shown in clinical trials that this seems to work, right, and that it can help to improve patients' outcomes.”
Listen at 14:00
- Paul Peter Takon Corporate outsourcing strategyPositive38:45
Companies should retain essential capabilities and outsource the rest.
“you should only own within your company what you really need to own and outsource everything else”
Listen at 38:45
- Paul Peter Takon Candel manufacturingNegative39:18
Manufacturing is not Candel’s core business.
“This is not our core business.”
Listen at 39:18
Large fixed costs can put a biotech company at risk.
“that puts your company at risk”
Listen at 40:16
- Paul Peter Takon Candel sales forcePositive42:12
Candel should bring its sales force in-house after approval.
“after approval, hoping that we get to that point and planning for success, at that time point is better, in my opinion, to bring in the sales force yourself”
Listen at 42:12
- Paul Peter Takon U.S. Agletimodgen candidatesPositive42:29
Most eligible U.S. patients are concentrated among a few hundred accounts.
“80% of the patients, 8-0, who are candidates for treatment in the US, are linked to not more than a few hundred accounts.”
Listen at 42:29
- Paul Peter Takon Candel commercial launchPositive42:39
A focused commercial effort can produce rapid sales uptake.
“you can have a very focused effort, actually, to get very steep uptake in sales”
Listen at 42:39
- Paul Peter Takon Agletimodgen pricingPositive48:51
Agletimodgen pricing is expected near the high end, up to approximately $250,000.
“we expect that we will definitely be at the higher end of this range that goes up to $250,000 more or less”
Listen at 48:51
- Paul Peter Takon AgletimodgenPositive49:14
Agletimodgen is generally well tolerated.
“This is generally well-tolerated.”
Listen at 49:14
- Paul Peter Takon AgletimodgenPositive49:21
Agletimodgen did not increase serious adverse events versus placebo.
“there was no increase in serious adverse events if you compare the aglatimidine group versus placebo”
Listen at 49:21
- Paul Peter Takon Agletimodgen treatment economicsPositive49:31
Agletimodgen does not create recurring healthcare-system costs.
“this is not a recurring cost to the healthcare system”
Listen at 49:31
- Paul Peter Takon Agletimodgen pricingPositive50:07
Additional benchmarking could support a higher Agletimodgen price.
“we could even go for a higher price”
Listen at 50:07
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.